Serum total IgG and IgG4 levels in thyroid eye disease

Aileen Sy
Rona Z Silkiss

Department of Ophthalmology,
California Pacific Medical Center,
San Francisco, CA, USA

Purpose: To investigate the relationship between immunoglobulin G (IgG)4-related disease (IgG4-RD) and thyroid eye disease (TED) with respect to IgG levels.

Patients and methods: A retrospective review of total IgG, IgG subclass, and thyroid stimulating immunoglobulin (TSI) levels in 24 patients with TED.

Results: Five patients (20.8%) demonstrated serum IgG4 levels consistent with IgG4-RD without any additional systemic disease. Total IgG and IgG subclass levels were found to be an inadequate proxy for TSI elevation.

Conclusion: There may be a subtype of TED patients with elevated IgG4 in the absence of IgG4-RD systemic findings.

Keywords: thyroid eye disease, IgG subclass, IgG4, Graves' disease, Graves' ophthalmopathy, IgG4-RD

Introduction

Immunoglobulin G (IgG)4-related disease (IgG4-RD) is a relatively recently described systemic, fibro-inflammatory disorder that affects multiple organ systems, including commonly the orbits.¹ Reports have identified IgG4-RD as an etiology of previously described cases of orbital inflammatory disease or pseudotumor.¹⁻³ The most common orbital inflammatory disease is thyroid eye disease (TED). Studies of elevated serum IgG4 levels in systemic Graves' disease and histopathologic analysis of thyroid stroma from Graves' disease patients have suggested a possible subpopulation of Graves' patients with elevated IgG4.^{4,5} However, the study of IgG4 levels in the TED subgroup has not been previously reported nor have IgG subclass levels been evaluated in TED at large. The authors sought to evaluate total IgG and IgG subclass levels, including IgG4, in a TED population to determine if a subset of this population demonstrated latent IgG4-RD. Additionally, the relationship among total IgG, IgG4, and thyroid stimulating immunoglobulin (TSI) levels was investigated.

Methods

TED patients in the practice of one author (RZS) between December 2013 and January 2015 were reviewed. Patients with total and IgG subclass and thyroid function tests were included in the study. None of the patients studied demonstrated systemic signs or symptoms of IgG4-RD. Those patients meeting the serum criteria for IgG4-RD by either serum IgG4 concentration ≥ 135 mg/dL (Umehara et al.) or ratio of IgG4/IgG $\geq 8\%$ (Masaki et al.) criteria were identified.^{6,7} No biopsies for histopathological

Correspondence: Aileen Sy and
Rona Z Silkiss
Department of Ophthalmology, California
Pacific Medical Center, 711 Van Ness
Avenue, San Francisco, CA 94102, USA
Tel +1 510 763 0881
Fax +1 510 763 0907
Email aileensy@gmail.com

review were evaluated. The authors present in brief five case reports of patients with TED who also met serum criteria for IgG4-RD, followed by a summary of total IgG, IgG subclass, and TSI levels.

Institutional review board (IRB) approval was obtained from the Sutter Health IRB for this retrospective review that waived the need for individual informed consent. The study adhered to the Declaration of Helsinki and the Health and Portability and Accountability Act regulations.

Results

A total of 24 patients with available subclass IgG levels and thyroid function tests were identified. Twenty of these patients had total IgG levels available. Of 24 patients, two (8.3%) were found to meet IgG4-RD criteria by serum level ≥ 135 mg/dL and three (12.5%) by IgG4/IgG ratio $\geq 8\%$.

Case 1

A 55-year-old woman presented with an insidious onset of left ocular proptosis of uncertain duration. She did not have any other systemic issues or medical diagnoses. Her visual acuity was 20/20 in both eyes. Examination demonstrated eyelid retraction with proptosis of the left eye (clinical activity score (CAS) 3). Magnetic resonance imaging (MRI) showed enhanced, thickened extraocular muscles, particularly the inferior and superior recti. Her TSI was 753%, total IgG 1,496 mg/dL, and IgG4 167 mg/dL with an IgG4/IgG ratio of 11.1%.

Case 2

A 39-year-old man presented with a 6-week history of proptosis and diplopia. He had no other systemic symptoms. Medical history was remarkable for the diagnosis of hyperthyroidism 1 year prior, for which he was taking methimazole. Visual acuity was 20/30 right eye and 20/20 left eye. Examination was significant for left upper lid retraction, and proptosis and chemosis in both eyes (CAS 4). MRI showed bilateral inferior and medial rectus muscle enlargement. TSI was 353%, total IgG 1,202 mg/dL, and IgG4 106.3 mg/dL with IgG4/IgG ratio of 8.8%.

Case 3

A 53-year-old woman presented with an insidious onset of diplopia and headaches. She had been recently diagnosed with hyperthyroidism and started on methimazole. Her medical history was notable for hypertension. She was otherwise symptomatically well. Her vision was 20/30 in the right eye and 20/25 in the left eye, with examination demonstrating left upper lid retraction, restriction of left supraduction, and

left proptosis (CAS 5). MRI showed enhancement of the inferior and lateral left extraocular muscles. Her TSI was 323%, total IgG 1,294 mg/dL, IgG4 123 mg/dL, and IgG4/IgG ratio was 9.5%.

Case 4

A 57-year-old woman presented with a 3-month history of bilateral proptosis and diplopia. She reported systemic symptoms of fatigue, weight gain, and dry skin consistent with hypothyroidism. Her history was significant for a thyroidectomy 20 years prior. She was being treated with levothyroxine. Her medical history was otherwise unremarkable. Visual acuity was 20/25 in both eyes and exam was significant for eyelid retraction and proptosis of both eyes (CAS 3). Her TSI was 354%, total IgG 987 mg/dL, and IgG4 97 mg/dL with an IgG4/IgG ratio of 9.8%. No MRI was available at the time of review.

Case 5

A 32-year-old woman presented with bilateral upper lid retraction and a prior diagnosis of hyperthyroidism treated with methimazole. She did not have any other systemic issues or medical diagnoses. Her visual acuity was 20/20 in both eyes and exam showed lid retraction of both eyelids (CAS 2). TSI was 539%, total IgG 1,335 mg/dL, and IgG4 153 mg/dL with IgG4/IgG ratio of 11.5%. An MRI was not available at the time of review.

Serum total IgG, IgG subclass, and TSI in TED patients

Data for total IgG, IgG subclass, and TSI are detailed in Table 1. Summary data were performed in STATA. There were 19 women and five men (M:F ratio 0.26:1), and the average age was 50.2 years (median age of 52 years, range 32 to 74 years). Serum total IgG in TED patients was $1,116.7 \pm 277.0$ mg/dL (range 499–1,546), IgG1 subclass 586.4 ± 184.6 mg/dL (range 318–974), IgG2 subclass 410.6 ± 170.8 mg/dL (range 102–863), and IgG3 subclass 78.9 ± 70.0 mg/dL (range 6–362). Serum IgG4 subclass was 59.7 ± 44.2 mg/dL (range 3.8–167) and TSI $386.2 \pm 191.8\%$ (range 24–753). All total IgG levels were within normal range, regardless of TSI elevation, and no particular IgG subclass correlated with TSI elevation. Additionally, there was no correlation found between CAS and total IgG or IgG4 subclass levels.

Discussion

The results of this study identify a small subset of TED patients with elevated serum IgG4 levels meeting serum

Table 1 Serum total IgG, IgG subclass, and TSI in TED patients

Case	Age (years)	Gender	Total IgG (mg/dL)	IgG1 (mg/dL)	IgG2 (mg/dL)	IgG3 (mg/dL)	IgG4 (mg/dL)	IgG4:IgG ratio	TSI (%)
1	55	F	1,496	760	558	94	167	0.112	753
2	39	M	1,202	542	584	105	106.3	0.088	353
3	53	F	1,294	649	572	80	123	0.095	323
4	57	F	987	556	250	19	97	0.098	354
5	60	M	832	409	400	76	64	0.077	393
6	53	F	N/A	323	202	36	31	N/A	516
7	35	M	N/A	708	295	31	26	N/A	353
8	64	F	N/A	845	438	102	55	N/A	287
9	47	F	951	439	504	362	32.5	0.034	599
10	32	M	N/A	359	469	59	17	N/A	377
11	33	F	1,545	815	715	76	55.2	0.036	<89 ^a
12	73	F	1,546	974	380	52	32.6	0.021	446
13	40	F	1,066	535	390	57	61	0.057	250
14	68	F	829	318	494	62	59	0.071	24 ^b
15	42	F	1,241	791	343	81	61	0.049	683
16	51	F	746	433	269	25	4.5	0.006	472
17	70	F	499	364	102	6	3.8	0.008	<89 ^c
18	36	M	1,033	452	460	77	38.2	0.037	569
19	57	F	972	565	220	63	7	0.007	579
20	74	F	1,191	676	296	184	90.4	0.076	474
21	50	F	983	611	286	43	60	0.061	257
22	32	F	1,335	469	863	67	153	0.115	539
23	22	F	1,314	813	344	78	66.4	0.051	401
24	62	F	1,272	668	420	58	20.7	0.016	<89 ^d
Mean (median)		M:F ratio	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	N/A	Mean (SD)
50.2 (52)		0.26:1	1,116.7 (277.0)	586.4 (184.6)	410.6 (170.8)	78.9 (70.0)	59.7 (44.2)	N/A	386.2 (191.8)

Notes: ^aPatient with elevated thyroid peroxidase antibody and thyroglobulin antibody consistent with Hashimoto's thyroiditis. ^bPatient with TSI 178% 1 year prior, with enlarged right inferior rectus on MRI. ^cPatient with TSI 339% 6 months prior, with enlarged right inferior and medial recti on MRI. ^dPatient with a 2-year history of TED prior to consultation.

Abbreviations: F, female; M, male; MRI, magnetic resonance imaging; N/A, not available; SD, standard deviation; TED, thyroid eye disease; TSI, thyroid stimulating immunoglobulin; IgG, immunoglobulin G.

IgG4-RD criteria but without findings of systemic IgG4-RD by symptomology and medical history. This study also reveals that total IgG levels were not an adequate proxy for either IgG4 or TSI elevation. Among TED patients, there did not appear to be a dominance of any one subclass of IgG, nor were high levels of TSI associated with elevation in total IgG or a specific IgG subclass.

Patients included in the study had clinical exam findings, imaging, and/or lab values consistent with TED but did not have other systemic symptoms or medical issues to indicate multi-system organ involvement characteristic of IgG4-RD. A case of concurrent IgG4-RD and TED has been described in the literature, but how commonly IgG4-RD or IgG4 elevation occurs in TED patients has not been reported.⁸ Serum IgG4 levels in Graves' thyroidopathy patients with systemic manifestations have been reported. In 1990, before the first descriptions of IgG4-RD, Weetman et al. investigated the levels of each IgG subtype in 10 Graves' disease patients and

found two patients with IgG4 levels greater than the 95th percentile of normal; however, only one of these patients had an IgG4 level ≥ 135 mg/dL.⁹ In 2014, Takeshima et al. studied 109 Graves' thyroidopathy patients and found seven (6.4%) had elevated serum IgG4 levels ≥ 135 mg/dL and three (2.8%) additional cases had IgG4/IgG ratios $\geq 8\%$.⁴ These patients were found to be older, with more hypoechoic areas on thyroid ultrasound. Three patients with elevated IgG4 levels also had CAS suggestive of ocular involvement (2.8%); however, there was no statistical difference in the incidence of ophthalmopathy by CAS or orbital imaging between the non-elevated and elevated IgG4 groups. Histopathologic study of stromal thyroid tissue from Graves' disease patients found 0.74% (11/1484) to have diffuse lymphoplasmacytic infiltration characteristic of IgG4-RD.⁵ Of these 11 cases, the investigators found only a portion had IgG4-positive plasma cells (45.5%; 0.33% overall).⁵ Further investigation into patients with ophthalmopathy

was not available. In our current study specific to Graves' ophthalmopathy patients, our results suggest a higher (8.3% by IgG4 level ≥ 135 mg/dL criteria or 20.8% by combined criteria) prevalence of serum IgG4 elevation among TED patients. In another study, orbital biopsies of patients with varying orbital diseases were studied for immunostaining with IgG4. None of the biopsies from TED patients had significant IgG4 staining.³ Biopsies for histopathological analysis were not available for our study.

Conclusion

The identification of a possible subgroup of TED patients with elevated IgG4 may aid in the further development of a treatment protocol for TED. While the use of IgG levels may not be an adequate proxy for TSI or TED, IgG4 levels may help to identify patients selectively more responsive to rituximab or other biologics, allowing for earlier and more effective treatment. It remains unclear whether the presence of IgG4 elevation in this subpopulation of TED patients indicates a more severe inflammatory disease course or predates latent IgG4-RD. Further immunologic evaluation of TED patients could provide insight into the pathogenesis of the disease and aid in the selection of biologic immune therapy.

Acknowledgment

The authors thank the Pacific Vision Foundation for their support of this research.

The abstract of this paper was presented at the ARVO Annual Meeting, May 3–7 2015 in Denver, CO, USA.

Disclosure

The authors report no conflicts of interest in this work.

References

1. McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part I: background and pathology. *Ophthalmol Plast Reconstr Surg*. 2015;31(2):83–88.
2. Andrew NH, Sladden N, Kearney DJ, Selva D. An analysis of IgG4-related disease (IgG4-RD) among idiopathic orbital inflammations and benign lymphoid hyperplasias using two consensus-based diagnostic criteria for IgG4-RD. *Br J Ophthalmol*. 2015;99(3):376–381.
3. Wong AJ, Planck SR, Choi D, et al. IgG4 immunostaining and its implications in orbital inflammatory disease. *PLoS One*. 2014;9(10):e109847.
4. Takeshima K, Inaba H, Furukawa Y, et al. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications. *Thyroid*. 2014;24(4):736–743.
5. Nishihara E, Hirokawa M, Ito M, Fukata S, Nakamura H, Amino N, Miyauchi A. Graves' disease patients with persistent hyperthyroidism and diffuse lymphoplasmacytic infiltration in the thyroid show no histopathological compatibility with IgG4-related disease. *PLoS One*. 2015;10(7):e0134143.
6. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. *Mod Rheumatol*. 2012;22(1):21–30.
7. Masaki Y, Kurose N, Yamamoto M, et al. Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease. *Int J Rheumatol*. 2012;2012:580814.
8. Kubota T, Moritani S, Terasaki H. Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder and Graves ophthalmopathy. *Arch Ophthalmol*. 2011;129(6):818–819.
9. Weetman AP, Byfield PG, Black C, Reimer CB. IgG heavy-chain subclass restriction of thyrotropin-binding inhibitory immunoglobulins in Graves' disease. *Eur J Clin Invest*. 1990;20(4):406–410.

International Medical Case Reports Journal

Publish your work in this journal

The International Medical Case Reports Journal is an international, peer-reviewed open-access journal publishing original case reports from all medical specialties. Previously unpublished medical posters are also accepted relating to any area of clinical or preclinical science. Submissions should not normally exceed 2,000 words or

Submit your manuscript here: <https://www.dovepress.com/international-medical-case-reports-journal-journal>

4 published pages including figures, diagrams and references. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress